Vfy.Ax
VFY.AX operates in the Advanced Medical Equipment & Technology industry, providing specialized healthcare services and equipment.
Business. VFY.AX operates in the Advanced Medical Equipment & Technology industry, providing specialized healthcare services and equipment.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
VFY.AX operates in the Advanced Medical Equipment & Technology industry, providing specialized healthcare services and equipment.
The company's capital structure is characterized by a high price-to-book ratio of 5.75 and a price-to-tangible-book ratio of 5.75, indicating that the market is valuing the company's equity at a premium relative to its book value. The debt-to-equity ratio is 0.01, suggesting a low level of leverage. However, the company has negative operating and free cash flows, with operating cash flow at -8,801,180 AUD and free cash flow at -32,558,240 AUD, which may raise concerns about its ability to fund operations and growth without external financing.
Profitability metrics show that the company is currently unprofitable, with a return on equity of -1.1371 and a return on assets of -1.0272. These negative returns indicate that the company is not generating sufficient returns to cover its cost of capital. The operating income is -14,529,050 AUD, and the net income is -32,710,470 AUD, both of which are significantly below the industry median for profitability metrics.
The company's revenue is concentrated in a single segment, as there are no disclosed segments in the financial data. Geographically, the company's exposure is not specified in the provided data, but the negative operating and free cash flows suggest that the company may be facing challenges in generating consistent revenue across different regions.
The company's growth trajectory is uncertain, as the provided data does not include specific outlook figures for the current or next fiscal year. However, the negative operating and free cash flows indicate that the company may be struggling to grow its revenue and improve its financial performance. The company's capital expenditure is minimal at -1,850 AUD, suggesting that it is not investing heavily in new projects or expansion.
The company faces several risk factors, including liquidity concerns due to negative net cash after subtracting total debt. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative operating and free cash flows may necessitate additional financing, which could lead to dilution of existing shareholders' equity. The risk assessment also highlights the potential for dilution, although the probability is currently low.
Recent events and filings do not provide specific details about the company's operations or financial performance. The company's financial snapshot indicates significant losses and negative cash flows, which may be a cause for concern among investors and analysts. The analyst estimates suggest a mean price target of 2.75 AUD, with a median price target of 2.75 AUD, indicating a slightly positive outlook despite the company's current financial challenges.
- The company has a high price-to-book ratio, indicating that the market is valuing its equity at a premium relative to its book value.
- The company is currently unprofitable, with negative returns on equity and assets.
- The company's revenue is concentrated in a single segment, and its geographic exposure is not specified.
- The company's growth trajectory is uncertain, with negative operating and free cash flows.
- The company faces liquidity concerns due to negative net cash after subtracting total debt.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,24 |
| Revenue | —no estimate | —no estimate | 1,8M AUD |
| Operating income | —no estimate | —no estimate | -17,6M AUD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- VFY.AX Market data — financials · 2026-05-29
- Vitrafy Life Sciences Ltd Market data — analyst estimates · 2026-05-29